Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Tobracin

    Tobramycin (Ophthalmic)
    Ophthalmic Solution 0.30% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as,

    Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.

    Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
    DosageView
    Ophthalmic ointment:
    • In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s).
    • In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually.
    Ophthalmic solution:
    • In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours.
    • In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed.
    Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
    Side effectsView
    The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
    ContraindicationsView
    It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
    PrecautionsView
    Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.
    InteractionsView
    Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
    Pregnancy & lactationView
    Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
    Overdose effectsView
    Sign and symptoms of overdose may be similar to side effects as described above.
    StorageView
    Protect from light, store in cool (below 25°C) & dry place. Keep out of reach of children. Used within 4 weeks after first opening.

    Tobracin

    Tobramycin (Ophthalmic)
    Ophthalmic Ointment 0.30% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as,

    Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.

    Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
    DosageView
    Ophthalmic ointment:
    • In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s).
    • In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually.
    Ophthalmic solution:
    • In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours.
    • In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed.
    Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
    Side effectsView
    The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
    ContraindicationsView
    It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
    PrecautionsView
    Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.
    InteractionsView
    Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
    Pregnancy & lactationView
    Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
    Overdose effectsView
    Sign and symptoms of overdose may be similar to side effects as described above.
    StorageView
    Protect from light, store in cool (below 25°C) & dry place. Keep out of reach of children. Used within 4 weeks after first opening.

    Tobracin D

    Dexamethasone + Tobramycin
    Ophthalmic Ointment 0.1%+0.3% Allopathic Ophthalmic steroid - antibiotic combined preparations

    Indications

    Pink eye

    Indication detailsView
    This sterile Eye Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
    Therapeutic classView
    Ophthalmic steroid - antibiotic combined preparations
    PharmacologyView
    Like other amino-glycosides, the bactericidal activity of Tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but at the present time, very little is known about this action. It is thought that inhibition of protein synthesis is due to an action on ribosome that causes bacterial misreading of messenger RNA. The action of Dexamethasone is to inhibit the phospholipase A2, the first step in prostaglandin synthesis. Also Dexamethasone inhibits the chemo-tactic infiltration of neutrophils into the site of inflammation. The result is that its anti-inflammatory activity is 25 times greater and its overall therapeutic effectiveness 8-10 times greater than that of hydrocortisone.
    DosageView
    Insert 1 drop into the conjunctival sac 3-5 times per day. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every 2 hours.
    Side effectsView
    The most frequent side effects to topical ocular Tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation.
    ContraindicationsView
    Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva. Mycobacterial infections of the eye caused by, but not limited to, acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of ocular structures. Untreated purulent infection of the eye. Hypersensitivity to any component of the medication.
    PrecautionsView
    Shake the bottle well before use. To prevent contamination do not touch the tip of the bottle to affected eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.
    InteractionsView
    No specific interaction studies were performed with this combination eye drops. In case of concomitant therapy with other topical ophthalmic medicines, an interval of 10 minutes should be allowed between successive applications.
    Pregnancy & lactationView
    Safety for use during pregnancy and lactation in humans has not been established
    Pediatric usageView
    Use in paediatric: Safety and effectiveness in paediatric patients below 2 years have not been established.
    Overdose effectsView
    Overdose of this eye drops may be flushed from the eye(s) with lukewarm tap water.
    StorageView
    Store at room temperature. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.

    Tobracin D

    Dexamethasone + Tobramycin
    Ophthalmic Solution 0.1%+0.3% Allopathic Ophthalmic steroid - antibiotic combined preparations

    Indications

    Pink eye

    Indication detailsView
    This sterile Eye Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
    Therapeutic classView
    Ophthalmic steroid - antibiotic combined preparations
    PharmacologyView
    Like other amino-glycosides, the bactericidal activity of Tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but at the present time, very little is known about this action. It is thought that inhibition of protein synthesis is due to an action on ribosome that causes bacterial misreading of messenger RNA. The action of Dexamethasone is to inhibit the phospholipase A2, the first step in prostaglandin synthesis. Also Dexamethasone inhibits the chemo-tactic infiltration of neutrophils into the site of inflammation. The result is that its anti-inflammatory activity is 25 times greater and its overall therapeutic effectiveness 8-10 times greater than that of hydrocortisone.
    DosageView
    Insert 1 drop into the conjunctival sac 3-5 times per day. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every 2 hours.
    Side effectsView
    The most frequent side effects to topical ocular Tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation.
    ContraindicationsView
    Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva. Mycobacterial infections of the eye caused by, but not limited to, acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of ocular structures. Untreated purulent infection of the eye. Hypersensitivity to any component of the medication.
    PrecautionsView
    Shake the bottle well before use. To prevent contamination do not touch the tip of the bottle to affected eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.
    InteractionsView
    No specific interaction studies were performed with this combination eye drops. In case of concomitant therapy with other topical ophthalmic medicines, an interval of 10 minutes should be allowed between successive applications.
    Pregnancy & lactationView
    Safety for use during pregnancy and lactation in humans has not been established
    Pediatric usageView
    Use in paediatric: Safety and effectiveness in paediatric patients below 2 years have not been established.
    Overdose effectsView
    Overdose of this eye drops may be flushed from the eye(s) with lukewarm tap water.
    StorageView
    Store at room temperature. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.

    Tobram

    Tobramycin (Ophthalmic)
    Ophthalmic Solution 0.30% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as,

    Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.

    Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
    DosageView
    Ophthalmic ointment:
    • In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s).
    • In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually.
    Ophthalmic solution:
    • In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours.
    • In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed.
    Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
    Side effectsView
    The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
    ContraindicationsView
    It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
    PrecautionsView
    Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.
    InteractionsView
    Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
    Pregnancy & lactationView
    Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
    Overdose effectsView
    Sign and symptoms of overdose may be similar to side effects as described above.
    StorageView
    Protect from light, store in cool (below 25°C) & dry place. Keep out of reach of children. Used within 4 weeks after first opening.

    Tobram-D

    Dexamethasone + Tobramycin
    Ophthalmic Solution 0.1%+0.3% Allopathic Ophthalmic steroid - antibiotic combined preparations

    Indications

    Pink eye

    Indication detailsView
    This sterile Eye Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
    Therapeutic classView
    Ophthalmic steroid - antibiotic combined preparations
    PharmacologyView
    Like other amino-glycosides, the bactericidal activity of Tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but at the present time, very little is known about this action. It is thought that inhibition of protein synthesis is due to an action on ribosome that causes bacterial misreading of messenger RNA. The action of Dexamethasone is to inhibit the phospholipase A2, the first step in prostaglandin synthesis. Also Dexamethasone inhibits the chemo-tactic infiltration of neutrophils into the site of inflammation. The result is that its anti-inflammatory activity is 25 times greater and its overall therapeutic effectiveness 8-10 times greater than that of hydrocortisone.
    DosageView
    Insert 1 drop into the conjunctival sac 3-5 times per day. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every 2 hours.
    Side effectsView
    The most frequent side effects to topical ocular Tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation.
    ContraindicationsView
    Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva. Mycobacterial infections of the eye caused by, but not limited to, acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of ocular structures. Untreated purulent infection of the eye. Hypersensitivity to any component of the medication.
    PrecautionsView
    Shake the bottle well before use. To prevent contamination do not touch the tip of the bottle to affected eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.
    InteractionsView
    No specific interaction studies were performed with this combination eye drops. In case of concomitant therapy with other topical ophthalmic medicines, an interval of 10 minutes should be allowed between successive applications.
    Pregnancy & lactationView
    Safety for use during pregnancy and lactation in humans has not been established
    Pediatric usageView
    Use in paediatric: Safety and effectiveness in paediatric patients below 2 years have not been established.
    Overdose effectsView
    Overdose of this eye drops may be flushed from the eye(s) with lukewarm tap water.
    StorageView
    Store at room temperature. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.

    Tobramin

    Tobramycin (Ophthalmic)
    Ophthalmic Solution 0.30% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as,

    Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.

    Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
    DosageView
    Ophthalmic ointment:
    • In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s).
    • In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually.
    Ophthalmic solution:
    • In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours.
    • In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed.
    Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
    Side effectsView
    The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
    ContraindicationsView
    It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
    PrecautionsView
    Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.
    InteractionsView
    Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
    Pregnancy & lactationView
    Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
    Overdose effectsView
    Sign and symptoms of overdose may be similar to side effects as described above.
    StorageView
    Protect from light, store in cool (below 25°C) & dry place. Keep out of reach of children. Used within 4 weeks after first opening.

    Tobrel

    Tobramycin (Ophthalmic)
    Ophthalmic Solution 0.30% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    Tobramycin is a topical antibiotic indicated in the treatment of external bacterial infections of the eye caused by susceptible organisms. Such as,

    Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus spp. of group A beta-hemolytic and some nonhemolytic species.

    Gram-negative bacteria: E.coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella spp., Proteusmirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella spp and some strains of Neisseria.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    Like other aminoglycosides, the bactericidal activity of Tobramycin is taken up into sensitive bacterial cells by an active transport process. Within the cell Tobramycin bind to the 30s, and to some extent to the 50s subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability.
    DosageView
    Ophthalmic ointment:
    • In mild to moderate infection, apply a small amount 2-3 times daily into the conjunctival sac(s).
    • In severe cases of infection, apply a small amount 3-4 times daily into the conjunctival sac(s) until improvement is obtained, then reduce the dose gradually.
    Ophthalmic solution:
    • In mild to moderate infections: Instill 1or 2 drops into the affected eye(s) every 4 hours.
    • In severe infections: Instill 2 drops into the affected eye(s) every hour until improvement is observed.
    Pediatric use: Safety and effectiveness in children below the age of 1 year have not been established.
    Side effectsView
    The most frequent side effect of Tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling.
    ContraindicationsView
    It is contraindicated in patients who are hypersensitive to Tobramycin or any of the ingredients of the preparation.
    PrecautionsView
    Minor sensitivity may occur to topically applied aminoglycosides in some patients. If a sensitivity reaction occurs, discontinue use. Prolonged use may result in overgrowth of nonsusceptible organisms and fungi.
    InteractionsView
    Care should be exercised when tobramycin is given to patients receiving other drugs with neuromauscular blocking agents or ototoxic.
    Pregnancy & lactationView
    Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should only be used during pregnancy, if the potential benefits outweigh the possible risk to the fetus. Drug may excreted into human milk. A decision should be made whether to discontinue nursing or to taking the drug.
    Overdose effectsView
    Sign and symptoms of overdose may be similar to side effects as described above.
    StorageView
    Protect from light, store in cool (below 25°C) & dry place. Keep out of reach of children. Used within 4 weeks after first opening.

    Tocef

    Cefixime Trihydrate
    Powder for Suspension 100 mg/5 ml Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

    Tocef

    Cefixime Trihydrate
    Capsule 400 mg Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

    Tocef

    Cefixime Trihydrate
    Capsule 200 mg Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

    Tocef DS

    Cefixime Trihydrate
    Powder for Suspension 200 mg/5 ml Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

    Tocit

    Tofacitinib
    Tablet 5 mg Allopathic Immunosuppressant

    Indications

    Ulcerative colitis

    Indication detailsView
    Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

    Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

    Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
    Therapeutic classView
    Immunosuppressant
    PharmacologyView
    Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.

    Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
    DosageView
    Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

    Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily.  Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

    Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
    Side effectsView
    The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
    PrecautionsView
    • Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections. 
    • Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
    • Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
    • Immunizations: Live vaccines: Avoid use with Tofacitinib.
    • Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
    InteractionsView
    • Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
    • Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
    • Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
    Pregnancy & lactationView
    Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
    Pediatric usageView
    Pediatric Use: The safety and effectiveness of Tofacitinib in pediatric patients have not been established.

    Geriatric Use: The frequency of serious infection among Tofacitinib-treated subjects 65 years of age and older was higher than among those under the age of 65. As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly.

    Moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function.
    StorageView
    Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.

    Tocit XR

    Tofacitinib
    Tablet (Extended Release) 11 mg Allopathic Immunosuppressant

    Indications

    Ulcerative colitis

    Indication detailsView
    Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

    Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

    Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
    Therapeutic classView
    Immunosuppressant
    PharmacologyView
    Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.

    Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
    DosageView
    Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

    Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily.  Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

    Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
    Side effectsView
    The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
    PrecautionsView
    • Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections. 
    • Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
    • Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
    • Immunizations: Live vaccines: Avoid use with Tofacitinib.
    • Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
    InteractionsView
    • Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
    • Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
    • Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
    Pregnancy & lactationView
    Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
    Pediatric usageView
    Pediatric Use: The safety and effectiveness of Tofacitinib in pediatric patients have not been established.

    Geriatric Use: The frequency of serious infection among Tofacitinib-treated subjects 65 years of age and older was higher than among those under the age of 65. As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly.

    Moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function.
    StorageView
    Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.

    Toco Soft

    Tocotrienol + Tocopherol
    Capsule 50 mg + 13.5 mg Herbal Herbal and Nutraceuticals

    Indications

    Maintain healthy skin, hair, nail, teeth, bone, eye and nervous system

    Indication detailsView
    • Supports healthy hair & skin
    • Supports brain health & cognitive function
    • Powerful antioxidant
    • Helps to maintain healthy blood vessels
    Therapeutic classView
    Herbal and Nutraceuticals
    PharmacologyView
    Vitamin E is a fat soluble vitamin. Structurally both tocotrienol and tocopherol have a chroman ring as the head but are distinguished by their side chain. Tocopherol has a saturated side chain whereas tocotrienol has three double bonds in its side chain. This is why tocotrienol is sometimes called the unsaturated vitamin E. While very similar in structure to tocopherol, research has shown that tocotrienols have additional biological activities which are not shown by the alpha-tocopherol.
    DosageView
    Adults and above 18 years: 1-2 capsules daily or as directed by the physician.
    Side effectsView
    Well tolerated in recommended dose.
    ContraindicationsView
    Contraindicated in patients with known hypersensitivity to any of the ingredients.
    InteractionsView
    Patients on cholesterol-lowering medication should only consume the product under medical supervision.
    Pregnancy & lactationView
    Not recommended for pregnant or lactating women.
    StorageView
    Store at a cool & dry place below 25°C. Protect from direct sunlight & moisture. Do not freeze.

    Tocoban

    Atosiban Acetate
    IV Infusion 37.5 mg/5 ml Allopathic Other preparations

    Indications

    Delay imminent pre-term birth

    Indication detailsView
    Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:
    • regular uterine contractions of at least 30 seconds duration at a rate of ≥4 per 30 minutes
    • a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥50%
    • a gestational age from 24 until 33 completed weeks
    • a normal fetal heart rate
    Therapeutic classView
    Other preparations
    PharmacologyView
    It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production. This ultimately prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels. This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence.

    Atosiban has more recently been found to act as a biased ligand at oxytocin receptors. It acts as an antagonist of Gq coupling, explaining the inhibition of the inositol triphosphate pathway thought to be responsible for the effect on uterine contraction, but acts as an agonist of Gi coupling. This agonism produces a pro-inflammatory effect in the human amnion, activating pro-inflammatory signal tranducer NF-κB. It is thought that this reduces atosiban's effectiveness compared to agents which do not produce inflammation as inflammatory mediators are known to play a role in the induction of labour.
    DosageView
    Atosiban is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Atosiban 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Atosiban 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Atosiban 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Atosiban therapy should preferably not exceed 330.75 mg of atosiban.
    Side effectsView
    Very common (affects more than 1 in 10 people): feeling sick (nausea).

    Common (affects less than 1 in 10 people): headache, feeling dizzy, hot flushes, being sick (vomiting), fast heartbeat, Low blood pressure. Signs may include feeling dizzy or light-headed, A reaction at the site where the injection was given, high blood sugar.

    Uncommon (affects less than 1 in 100 people): high temperature (fever), difficulty sleeping (insomnia), itching, rash.
    ContraindicationsView
    Atosiban must not be used in the following conditions:
    • Gestational age below 24 or over 33 completed weeks
    • Premature rupture of the membranes >30 weeks of gestation
    • Abnormal foetal heart rate
    • Antepartum uterine haemorrhage requiring immediate delivery
    • Eclampsia and severe pre-eclampsia requiring delivery
    • Intrauterine foetal death
    • Suspected intrauterine infection
    • Placenta praevia
    • Abruptio placenta
    • Any other conditions of the mother or foetus, in which continuation of pregnancy is hazardous
    PrecautionsView
    • When Atosiban is used in patients in whom premature rupture of membranes cannot be excluded, the benefits of delaying delivery should be balanced against the potential risk of chorioamnionitis.
    • There is no experience with Atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of Atosiban is excreted in the urine. In patients with impaired hepatic function, Atosiban should be used with caution
    • There is only limited clinical experience in the use of Atosiban in multiple pregnancies or the gestational age group between 24 and 27 weeks, because of the small number of patients treated. The benefit of Atosiban in these subgroups is therefore uncertain.
    • Re-treatment with Atosiban is possible, but there is only limited clinical experience available with multiple re-treatments, up to 3 re-treatments.
    • In case of intrauterine growth retardation, the decision to continue or reinitiate the administration of Atosiban depends on the assessment of fetal maturity.
    • Monitoring of uterine contractions and fetal heart rate during administration of Atosiban and in case of persistent uterine contractions should be considered.
    • As an antagonist of oxytocin, Atosiban may theoretically facilitate uterine relaxation and postpartum bleeding therefore blood loss after delivery should be monitored. However, inadequate uterus contraction postpartum was not observed during the clinical trials.
    • Multiple pregnancy and medicinal products with tocolytic activity like calcium channel blockers and beta- mimetics are known to be associated with increased risk of pulmonary oedema. Therefore, Atosiban should be used with caution in case of multiple pregnancy and/or concomitant administration of other medicinal products with tocolytic activity
    InteractionsView
    It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes. Interaction studies have been performed with labetalol and betamethasone in healthy, female volunteers. No clinically relevant interaction was found between atosiban and bethamethasone or labetalol.
    Pregnancy & lactationView
    If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are given
    Atosiban.
    StorageView
    Store in a refrigerator (2°C-8°C). Keep away from light & moisture. Keep out of the reach of children.

    Tocoban

    Atosiban Acetate
    IV Infusion 6.75 mg/0.9 ml Allopathic Other preparations

    Indications

    Delay imminent pre-term birth

    Indication detailsView
    Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:
    • regular uterine contractions of at least 30 seconds duration at a rate of ≥4 per 30 minutes
    • a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥50%
    • a gestational age from 24 until 33 completed weeks
    • a normal fetal heart rate
    Therapeutic classView
    Other preparations
    PharmacologyView
    It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production. This ultimately prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels. This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence.

    Atosiban has more recently been found to act as a biased ligand at oxytocin receptors. It acts as an antagonist of Gq coupling, explaining the inhibition of the inositol triphosphate pathway thought to be responsible for the effect on uterine contraction, but acts as an agonist of Gi coupling. This agonism produces a pro-inflammatory effect in the human amnion, activating pro-inflammatory signal tranducer NF-κB. It is thought that this reduces atosiban's effectiveness compared to agents which do not produce inflammation as inflammatory mediators are known to play a role in the induction of labour.
    DosageView
    Atosiban is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Atosiban 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Atosiban 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Atosiban 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Atosiban therapy should preferably not exceed 330.75 mg of atosiban.
    Side effectsView
    Very common (affects more than 1 in 10 people): feeling sick (nausea).

    Common (affects less than 1 in 10 people): headache, feeling dizzy, hot flushes, being sick (vomiting), fast heartbeat, Low blood pressure. Signs may include feeling dizzy or light-headed, A reaction at the site where the injection was given, high blood sugar.

    Uncommon (affects less than 1 in 100 people): high temperature (fever), difficulty sleeping (insomnia), itching, rash.
    ContraindicationsView
    Atosiban must not be used in the following conditions:
    • Gestational age below 24 or over 33 completed weeks
    • Premature rupture of the membranes >30 weeks of gestation
    • Abnormal foetal heart rate
    • Antepartum uterine haemorrhage requiring immediate delivery
    • Eclampsia and severe pre-eclampsia requiring delivery
    • Intrauterine foetal death
    • Suspected intrauterine infection
    • Placenta praevia
    • Abruptio placenta
    • Any other conditions of the mother or foetus, in which continuation of pregnancy is hazardous
    PrecautionsView
    • When Atosiban is used in patients in whom premature rupture of membranes cannot be excluded, the benefits of delaying delivery should be balanced against the potential risk of chorioamnionitis.
    • There is no experience with Atosiban treatment in patients with impaired function of the liver or kidneys. Renal impairment is not likely to warrant a dose adjustment, since only a small extent of Atosiban is excreted in the urine. In patients with impaired hepatic function, Atosiban should be used with caution
    • There is only limited clinical experience in the use of Atosiban in multiple pregnancies or the gestational age group between 24 and 27 weeks, because of the small number of patients treated. The benefit of Atosiban in these subgroups is therefore uncertain.
    • Re-treatment with Atosiban is possible, but there is only limited clinical experience available with multiple re-treatments, up to 3 re-treatments.
    • In case of intrauterine growth retardation, the decision to continue or reinitiate the administration of Atosiban depends on the assessment of fetal maturity.
    • Monitoring of uterine contractions and fetal heart rate during administration of Atosiban and in case of persistent uterine contractions should be considered.
    • As an antagonist of oxytocin, Atosiban may theoretically facilitate uterine relaxation and postpartum bleeding therefore blood loss after delivery should be monitored. However, inadequate uterus contraction postpartum was not observed during the clinical trials.
    • Multiple pregnancy and medicinal products with tocolytic activity like calcium channel blockers and beta- mimetics are known to be associated with increased risk of pulmonary oedema. Therefore, Atosiban should be used with caution in case of multiple pregnancy and/or concomitant administration of other medicinal products with tocolytic activity
    InteractionsView
    It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes. Interaction studies have been performed with labetalol and betamethasone in healthy, female volunteers. No clinically relevant interaction was found between atosiban and bethamethasone or labetalol.
    Pregnancy & lactationView
    If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are given
    Atosiban.
    StorageView
    Store in a refrigerator (2°C-8°C). Keep away from light & moisture. Keep out of the reach of children.

    Todol

    Ketorolac Tromethamine
    IM/IV Injection 60 mg/2 ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Todol

    Ketorolac Tromethamine (Ophthalmic)
    Ophthalmic Solution 0.50% Allopathic Non opioid analgesics

    Indications

    Postoperative eye inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for seasonal allergic conjunctivitis and for pain and inflammation in ocular surgery. It is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.
    Therapeutic classView
    Non opioid analgesics, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) chemically related to indomethacin and tolmetin. Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medications. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity. However, inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation may also contribute to the analgesic effect. In terms of the ophthalmic applications of ketorolac - ocular administration of ketorolac reduces prostaglandin E2 levels in aqueous humor, secondary to inhibition of prostaglandin biosynthesis.
    DosageView
    For the treatment of relief of ocular itching due to seasonal allergic conjunctivitis, one drop (0.25 mg) four times a day. For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop should be applied to the affected eye(s) four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period. It has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
    Side effectsView
    Transient stinging and burning on instillation, allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis and superficial ocular infections. Corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision)
    ContraindicationsView
    Contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.
    PrecautionsView
    All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDS and topical steroids may increase the potential for healing problems. Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.

    There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. With some nonsteroidal antiinflammatory drugs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues in conjunction with ocular surgery.
    InteractionsView
    No information available.
    Pregnancy & lactationView
    Pregnancy Category C: There is no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The use of drug during late pregnancy should be avoided.

    Nursing Mothers: Caution should be exercised when ophthalmic solution is administered to a nursing woman.
    Pediatric usageView
    Pediatric Use: Safety and efficacy in pediatric patients below the age of 3 have not been established.

    Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
    StorageView
    Store in a cool and dry place, away from light Keep out of reach of children.

    Todol

    Ketorolac Tromethamine
    IM/IV Injection 30 mg/ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.